Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN001 mRNA Vaccine for Herpes Zoster in Healthy Adults 50-79 Years Old
NCT07205796Phase 2Not yet recruiting
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd.
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
A Phase 2 trial of IN001 in herpes zoster (HZ), sponsored by Shenzhen Shenxin Biotechnology Co., Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
IN001
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07205796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205796.